ABBV vs GSK vs NVS Stock Comparison

AbbVie, Gsk and Novartis Ag Prices as of Nov 13, 2026 Peers: Industry group
ABBV AbbVie Inc.
$295.14 +4.1% 1M +27.1% 1Y
Market cap
$521.78B
P/E
50.5x
Revenue (TTM)
$66.01B
Div. yield
–
Pharmaceuticals Healthcare
4 wins
GSK GSK plc
$50.45 +5.4% 1M +4.8% 1Y
Market cap
$102.42B
P/E
8.1x
Revenue (TTM)
$76.96B
Div. yield
–
Pharmaceuticals Healthcare
5 wins
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$311.92B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare

Head to Head

9 decided of 12

Gsk leads on 5 of the 12 questions below (Gsk 5, AbbVie 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABBVGSKNVSLeader
Larger companyMarket capitalisation $521.78B $102.42B $311.92B ABBV
Cheaper on earningsLower P/E, profitable companies only 50.5x 8.1x 17.9x GSK
Cheaper on forward earningsLower price / next fiscal year consensus EPS 22.0x 9.9x 17.1x GSK
Faster revenue growthRevenue growth, trailing twelve months +10.7% +82.9% — GSK
More profitableNet margin, trailing twelve months 15.7% 16.4% — GSK
Better return on capitalReturn on invested capital 24.3% — — –
Less leveragedLower net debt / EBITDA 2.4x — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +27.1% +4.8% +21.7% ABBV
Better 5-year returnAnnualised price return, 5 years +20.3%/yr +3.1%/yr +14.3%/yr ABBV
Less volatileAnnualised volatility, 1 year 25.3% 26.4% 27.8% ABBV
Higher overall scoreMean of the five percentile scores vs peers 70/100 79/100 — GSK

Percentile Scorecard

ABBVGSKNVS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABBVGSKNVS
Valuation 90 #68 of 660 90 #64 of 660 96 #26 of 660
Growth 67 #204 of 619 72 #173 of 619 –
Profitability 96 #23 of 595 96 #24 of 595 –
Financial Health 15 #580 of 683 51 #337 of 683 –
Shareholder Returns 81 #89 of 459 85 #71 of 459 79 #97 of 459
Overall 70 79 –
  • ABBV ranked among 695 companies in Pharmaceuticals and Biotechnology
  • GSK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABBVGSKNVSSPY
1 month +4.1%+5.4%+9.3% -2.0%
3 months +18.3%+1.8%+6.4% -2.8%
6 months +40.3%+1.6%+8.4% +2.0%
Year to date +29.2%+2.9%+16.5% +10.6%
1 year +27.1%+4.8%+21.7% +12.2%
3 years +113.8%+46.3%+69.2% +68.1%
3 years, per year +28.8%+13.5%+19.2% +18.9%
5 years +152.3%+16.4%+94.6% +61.4%
5 years, per year +20.3%+3.1%+14.3% +10.1%
10 years +367.7%+28.7%+118.5% +248.5%
10 years, per year +16.7%+2.6%+8.1% +13.3%

Risk

MeasureABBVGSKNVSSPY
Volatility, 1Y 25.3%26.4%27.8% 13.6%
Downside volatility, 1Y 24.1%24.0%30.0% 13.9%
Beta vs S&P 500, 1Y -0.020.280.36 1.00
Return / volatility, 1Y 1.070.180.78 0.90
Max drawdown, 5Y -24.3%-38.8%-20.4% -25.4%
From 52-week high 0.0%-17.5%-4.8% -3.2%
52-week high $295.14$61.18$168.62 $779.14
52-week low $197.38$46.11$124.36 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABBVGSKNVS
P/E now vs peer median 50.5xmedian 17.0x 8.1xmedian 17.0x 17.9xmedian 17.0x
P/S now vs peer median 7.9xmedian 8.4x 1.4xmedian 8.4x 5.1xmedian 8.4x
EV/EBITDA now vs peer median 20.4xmedian 14.6x —median 14.6x —median 14.6x
P/FCF now vs peer median 27.6xmedian 19.0x —median 19.0x 14.3xmedian 19.0x
P/B now vs peer median -113.8xmedian 2.0x 4.5xmedian 2.0x —median 2.0x
PEG now vs peer median 3.03median 0.43 0.43median 0.43 —median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABBVGSKNVS
Revenue $66.01B $76.96B –
Gross profit $48.67B $56.19B –
Operating income $21.23B $17.15B –
Net income $10.35B $2.75B –
Free cash flow $18.87B – –
R&D $9.96B $19.61B –
EPS (diluted) $5.84 $6.12 –
Cash & equivalents $10.77B $3.88B $400.00M
Total debt $80.90B -$31.50B –
Shares (diluted) 1.77B 2.06B 1.96B
Enterprise value $489.79B $85.26B $285.16B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABBVGSKNVS
P/E 50.5x 8.1x 17.9x
P/FCF 27.6x – 14.3x
P/Operating cash flow 26.0x – –
P/S 7.9x 1.4x 5.1x
P/B -113.8x 4.5x –
P/Tangible book -8.5x -12.1x –
EV/EBITDA 20.4x – –
EV/EBIT 27.9x 4.3x –
EV/Revenue 9.0x 1.0x –
EV/FCF 31.4x – –
EV/Operating cash flow 29.5x – –
PEG (3Y EPS CAGR) 3.03 0.43 –

Growth

14 metrics
MetricABBVGSKNVS
Revenue growth (1Y) 10.7% 82.9% –
Revenue CAGR (3Y) 6.2% 28.3% –
Gross profit growth (1Y) 17.0% 84.8% –
Gross profit CAGR (3Y) 10.3% 29.1% –
Operating income growth (1Y) 134.9% 73.5% –
Operating income CAGR (3Y) 12.1% 20.2% –
Net income growth (1Y) 331.9% -70.9% –
Net income CAGR (3Y) 16.6% -55.5% –
EPS growth (1Y) 333.1% 75.6% –
EPS CAGR (3Y) 16.6% 18.8% –
Operating cash flow growth (1Y) -3.7% – –
Operating cash flow CAGR (3Y) -7.7% – –
Free cash flow growth (1Y) -4.1% – –
Free cash flow CAGR (3Y) -8.6% – –

Profitability

14 metrics
MetricABBVGSKNVS
Gross margin 73.7% 73.0% –
EBITDA margin 43.9% – –
Operating margin 32.2% 22.3% –
Pretax margin 19.4% 20.5% –
Net margin 15.7% 16.4% –
FCF margin 28.6% – –
Operating cash flow margin 30.4% – –
Return on equity – 71.9% –
Return on assets 7.3% 19.2% –
Return on invested capital 24.3% – –
Return on capital employed 21.6% 14.8% –
Asset turnover 0.5x 0.9x –
Cash conversion (OCF / net income) 1.9x – –
Stock comp / revenue 1.4% – –

Financial Health

11 metrics
MetricABBVGSKNVS
Debt / assets 54.8% -33.2% –
Debt / equity -17.7x -1.3x –
Net debt / EBITDA 2.4x – –
Debt / FCF 4.3x – –
Liabilities / assets 103.1% 74.4% –
Equity / assets -3.1% 25.6% –
Interest coverage – 10.1x –
Current ratio 0.9x -0.9x –
Quick ratio 0.6x -0.5x –
Cash ratio 0.2x -0.1x –
Altman Z-score 2.78 3.22 –

Shareholder Returns

7 metrics
MetricABBVGSKNVS
Dividend yield 2.3% 4.5% 3.0%
Net buyback yield 0.3% – –
Shareholder yield 2.6% 4.5% 3.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABBVGSKNVS
Forward P/E 22.0xFY2026 9.9xFY2026 17.1xFY2026
EPS, next fiscal year $13.43FY2026 $5.08FY2026 $9.38FY2026
EPS growth, next FY +34.3%FY2026 +8.1%FY2026 +4.5%FY2026
EPS growth, the year after +24.3% +3.1% +0.9%
Revenue, next fiscal year $69.64BFY2026 $48.21BFY2026 $53.97BFY2026
Revenue growth, next FY +13.9%FY2026 +8.0%FY2026 -1.0%FY2026
Revenue growth, the year after -0.4% +0.5% +19.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABBVGSKNVS
Held by institutions 74.9% 16.0% 7.0%
Institutions holding 4,183 1,040 1,610
Change in shares held, QoQ +2.6% -7.4% -6.0%
Institutions buying 2,206 484 662
Institutions selling 1,507 336 562
Buyers to sellers 1.46 1.44 1.18

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABBVGSKNVS
ABBV 1.00 0.43 0.52
GSK 0.43 1.00 0.64
NVS 0.52 0.64 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABBV, GSK and NVS?

AbbVie (ABBV) is the largest by market capitalisation: AbbVie (ABBV) $521.78B, Gsk (GSK) $102.42B, Novartis Ag (NVS) $311.92B.

Which stock is cheaper, ABBV, GSK and NVS?

Gsk (GSK) trades on the lowest price-to-earnings ratio (AbbVie (ABBV) 50.5x, Gsk (GSK) 8.1x, Novartis Ag (NVS) 17.9x). On next year's consensus earnings, Gsk (GSK) is cheapest (AbbVie (ABBV) 22.0x, Gsk (GSK) 9.9x, Novartis Ag (NVS) 17.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Gsk (GSK) grew revenue fastest over the trailing twelve months: AbbVie (ABBV) +10.7%, Gsk (GSK) +82.9%.

Which company is more profitable?

Gsk (GSK) has the highest net margin (AbbVie (ABBV) 15.7%, Gsk (GSK) 16.4%).

Which stock has performed better?

Over the past year AbbVie (ABBV) returned the most: AbbVie (ABBV) +27.1%, Gsk (GSK) +4.8%, Novartis Ag (NVS) +21.7%. Over five years, AbbVie (ABBV) compounded fastest (AbbVie (ABBV) +20.3%/yr, Gsk (GSK) +3.1%/yr, Novartis Ag (NVS) +14.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, AbbVie (ABBV) has been the steadiest (AbbVie (ABBV) 25.3%, Gsk (GSK) 26.4%, Novartis Ag (NVS) 27.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABBV, GSK and NVS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Gsk (GSK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.